Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Core Viewpoint - Arvinas, Inc. is set to review its fourth quarter and full year 2025 financial results and provide a corporate update on February 24, 2026, at 8:00 a.m. ET [1] Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing a new class of drugs based on targeted protein degradation [3] - The company utilizes its PROTAC (PROteolysis TArgeting Chimera) platform to create therapies that degrade disease-causing proteins by leveraging the body's natural protein disposal system [3] - Arvinas is advancing multiple investigational drugs through clinical development, including: - ARV-102, targeting LRRK2 for neurodegenerative disorders - ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers - ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma - Vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer [3]